MRNA therapy for Fabry disease
US9308281B2 · kind B2 · utility
34Cited by
209References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2014 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | Jun 18, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.